Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
出版年份 2019 全文链接
标题
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
作者
关键词
-
出版物
Scientific Reports
Volume 9, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-10
DOI
10.1038/s41598-019-44874-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- Bispecific antibody based therapeutics: Strengths and challenges
- (2018) Archana Thakur et al. BLOOD REVIEWS
- Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study
- (2018) Anas M. Saad et al. BMC CANCER
- Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy
- (2018) Hadi Nasiri et al. JOURNAL OF CELLULAR PHYSIOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Gastric cancer: epidemiology, prevention, classification, and treatment
- (2018) Robert Sitarz et al. Cancer Management and Research
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
- (2018) Karie Runcie et al. MOLECULAR MEDICINE
- Emerging Therapies in the Management of Advanced-Stage Gastric Cancer
- (2018) Vivek Kumar et al. Frontiers in Pharmacology
- Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
- (2018) Sebastian Kobold et al. Frontiers in Oncology
- Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
- (2017) Prabhsimranjot Singh et al. Journal of Hematology & Oncology
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
- (2017) Isabel Corraliza-Gorjón et al. Frontiers in Immunology
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
- (2016) M. Dorywalska et al. MOLECULAR CANCER THERAPEUTICS
- Claudins in cancer: bench to bedside
- (2016) Makoto Osanai et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX
- (2016) Domenica Rea et al. Biomed Research International
- An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma
- (2015) Nitya S. Ramadoss et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
- (2015) Pavel Strop et al. NATURE BIOTECHNOLOGY
- Blinatumomab approved for rare leukemia
- (2014) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
- (2014) Lindsey M. Hoffman et al. Frontiers in Oncology
- Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
- (2012) Pavel Strop et al. JOURNAL OF MOLECULAR BIOLOGY
- Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
- (2011) Özlem Türeci et al. GENE
- Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations
- (2010) Yasufumi Kato et al. Journal of Thoracic Oncology
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study
- (2009) Hyun Ju Lee et al. LUNG CANCER
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started